Background. We and others have demonstrated that a low level of donor cell chimerism was present for years after transplantation in tissues and peripheral blood of heart and lung recipients; it was associated, in the latter, with a lower incidence of chronic rejection. To augment this phenomenon, we initiated a trial combining simultaneous infusion of donor bone marrow with heart or lung allotransplantation.
Methods. Between September 1993 and January 1995, 15 nonconditioned patients received either heart (n = 10) or lung (n = 5) allografts concurrent Iv with an infusion of unmodified donor bone marrow 13.0 x 10~ cells/kg), and were maintained on an immunosuppressive regimen consisting of tacrolimus and steroids. W e and others have recentlv demonstrated that a low level at donor cells was detectable in the peripheral blood and tissues ot long-surviving recipients or liver [11, kidney [2) , heart [31. lung, and heart-lung Hi allografts. This phenomenon ot donor cell chimerism, which occurs bv seeding of the host's tissues with cells from the graft [5, 61, was associated with a lower incidence or _ ~ronic rejection in tun!!; recipients [oll. To .lugment aonor cell chimensm, we initiated a prospective trial combining the simultaneous IntuslOn ot unmodified donor bone marrow and transplantation or heart or lung ,lllogratts mto nonconditioned reCipients. Reported herein IS the outcome or the first 15 panents in this study.
Patients and Methods
Between Seotember 1993 and lanuarv 1995. 13 patients received co~bined intusion ot donor bone marrow and transplantation ot either heart In = ttl) or lun~ .lllogratts .) 1995 bv The Societv or ThoraCIC Sur~eons
Results. There was no complication associated with the infusion of donor bone marrow. Chimerism was detectable in 73% of bone marrow-augmented patients up to the last sample tested. Of the 5 control recipients who did not receive bone marrow infusion. only 1 had detectable chimerism by flow on postoperative day 15, which dwindled to an undetectable level by postoperative day 36. None of the patients had evidence of donor-specific immune modulation by mixed lymphocyte reaction.
Conclusions. The combined infusion of donor bone marrow and heart or lung transplantation, without preconditioning of the recipient, is safe and is associated with an augmentation of donor cell chimerism.
(Ann TIiorac Surg 1995;60:1015-20> = 102 days. These patients, all primary transplant recipients ot cadaveric organs, were not conditioned by cytoablative or cytoreductive regimen before transplantation. Furthermore, all recipients had a panel reactive antibody titer of less than 10%, and none had a positive lymphocytotoxic crossma.tch. The mean number of HLA mismatches was 4.5 :: 1.2 (range, 3 to 6), with no patient ha\"Ulg complete HLA compatibility with the donor.
Bone Marrow Preparation and Infusion
Details of bone marrow preparation are described elsewhere [71. Brietlv, thoracolumbar vertebrae were retrieved from the donor. Marrow cells from chipped-off cancellous bone were passivelv released into a processing medium, filtered, washed. and resuspended in a suspension medium at a concentration of 2 x 10 7 cellsl mL The cell suspension was stored at 4°C until infusion. Cell viability was determined bv trypan blue dye exclusion. and samples ot processed bone marrow cells were retained for microbial testing and routine progenitor cell assays. When the recipient was readv to receive bone marrow, a total of 3.0 x lOll unmodified cells/kg of bodv weight were resuspended in 200 mL of the suspension medium and infused over a period of 15 to 20 minutes via a central venous line. The bone marrow was usually infused between 6 to 10 hours after revascularization of the transplanted organ.
Immunosuppression
Immunosuppression consisted of tacrolimus (FK506 [Prografl; Fujisawa USA. Deerfield, IL) and steroids, as previously described [81. During the first postoperative month, the dosage of tacrolimus was targeted to maintain whole blood trough levels of 15 to 20 ng/mL which, depending on the side effects and history of reiection, was gradually reduced to achieve levels of "5 to 15 ng/mL.
Methylprednisolone (1 g) was given intraoperatively before revascularization of the organ. Except in the first heart recipient, this was followed in all other patients by a short course of steroid recycle starting on postoperative day (POD) 1 with 200 mg/day and tapering to 20 mg/day by POD 5. Further steroid reductions were individually tailored according to allograft function. Azathioprine was added if there was recurrent or recalcitrant rejection, or when renal dysfunction necessitated the administration of a lower than required dose of tacrolimus. Reiection was treated initially with steroid boluses (1 g methylprednisolone/day x 3), whereas OKTI was resel'\'ed for steroid-resistant rejection.
In Vitro Monitoring
Mononuclear cells from recipients' peripheral blood (PBMC) were obtained preoperatively and biweeklv in the first postoperative month, and bimonthly thereafter for detection of donor cells and for immunolOgiC monitoring.
Detection of Chimerism
FLOW CYTOMETRY. For immunocytochemical staining, primary mouse-anti-human monoclonal antibodies directed against the polvrnorphic epitopes of either HLA class I or class II (to distinguish donor from recipient HLA alleles) were used. These primary monoclonal antibodies were labeled by either fluorescein isothiocvanate-or phycoerythrin-conjugated goat-anti-mouse secondary antibodies. The specificity and optimal dilution of these antibodies were determined using donor splenocvtes and the recipient's pretransplantation PBMC. 
Immune Monitoring
Ann Thorac Surg
The in vitro immune status of the recipients, before and after transplantation. was assessed by the proliferative response of their PBMC to mitogens (concanavalin A. phytohemagglutinin), and recall antigens (tetanus toxoid) by mixed l\'mphocyte reactions (MLR) and by cellmediated Ivmphocvtotoxicitv assavs. The MLR cultures were carried out using 'Y-irradiated donor splenocytes and third-partv PBMC as stimulators (5 x 10 4 cells), and recipient PBMC as responders (5 X 10 4 cells). The cells were cultured at 3iOC for 6 davs in 5·/0 CO~ in air.
eH)-thymidine (1 ILCil was add~d to each weil at the beginning of the final 20 hours, and its degree of incorporation was determined by liquid scintillation counting. For cell-mediated lvmphocytotoxicitv assays, phytohemogglutinin-activated 51 Cr-labeled donor splenocvtes and third-party PBMC were used as targets to eval~ate the effector function of 5-to 6-day MLR-cultured recipient's PBMe. Various effector:target ratios ranging from 10:1 to 40:1 were used.
Results

Clinical Course
BONE MARROW AUGMENTED PATIENTS. The infusion of donor bone marrow was well tolerated. None of the 15 recipients had graft-versus-host disease or complications related to the infusion of donor bone marrow. All patients, except 1. are alive with good allograft function ( Table 1 ). The single death occurred in a heart recipient (patient 5) who died at home of a pulmonary embolus on POD 267. One week before his death, a routine right heart catheterization revealed normal cardiac function. At autopsy, there was no evidence of acute or chronic rejection in the transplanted heart (Fig 1) . In 1 heart recipient (patient 10), who had been receiving aspirin preoperativel\', a duodenal perforation developed on POD 3. In another heart recipient (patient 1), a benign duodenal ulcer developed on POD 23i that was successfully treated, whereas an additional heart recipient (patient 8) had Acinetobacter sepsis from a pneumonia on POD 92, which resolved after appropriate therapy. Furthermore, two single-lung recipients (patients 14 and 15), who received an allograft from the same donor, suffered moderate to severe primary graft dvsfunction (preservation injurY). which in 1 (patient 14) necessitated .;upport with an extra corporeal membrane oxygenator tor 3 days. Two other lung recipients had Candida albicans in bronchoalveolar lavage on POD 13i and 221 respectivelv. and 1 hadA5pergillusfumi~atus (patient 13) on POD 58. All were successfully treated.
CONTROLS. Heart or lung recipients for whom bone marrow was not available, due to our inability to obtain permission to retrieve cadaveric vertebral bodies, were used as contemporaneous controls. All 4 heart recipients are alive with good graft function, whereas the single lung recipient (patient 20) died on POD 104 due to complications related to preservation injury. This lung recipient required perioperative support with an extra- :: corporeal membrane oxvgenator because ot primary gralt failure.
Rejection
In the 10 heart-bone marrow recipients, the rate of rejection tgrade ~ 3A [9]) during the first 100 davs alter transplantation was 0.5 episodes, as compared with 1.0 (p = 0.2i bv Fisher'S exact test) in a histoncal control group ot 26 heart recipients. who receIved an identical immunosuppressive regimen without bone marrow infusion. Onlv 1 heart recipient (patient 3 (no steroid recycle during the first 5 postoperative days), had steroid-resistant rejection that required a 5-day course of 0KT3 for its resolution. Furthermore, 3 additional heart recipients required azathioprine because of persistent low-grade (:s grade 2) rejection and high serum creatinine levels that precluded the use of therapeutic doses of tacrolimus. Of the 5 lung-bone marrow recipients, 3 had mild to moderate rejection (grade > II [lOll on POD 11, 32, and 53 respectively, whereas 2 had a rejection-free postoperative course.
DonOT Chimerism
Detection of donor cells was feasible in all bone marrowaugmented and nonaugmented patients by either flow cytometry or polymerase chain reaction. Control patients had no evidence of donor-cell chimerism in their PBMC at the most recent sample tested (Table 2) , On the contrary, 11115 study patients (73%) exhibited stable donor cell chimerism for up to 220 days after transplantation. It must be emphasized. however, that bone marrow-augmented recipients who were negative by polymerase chain reaction for donor cell chimerism in the last sample tested were positive in all previous analyses.
In Vitro Immune Testing
The unavailability of donor splenocytes precluded in vitro immune monitoring in 8115 (53%) of bone marrowaugmented recipients. None of the bone marrowaugmented (n = 7) or nonaugmented (n = 4) patients in whom testing was feasible exhibited any evidence ot donor-specific immune modulation (by MLR) for up to 210 days after transplantation (Table 3) . It is nevertheless noteworthy that there was a trend in the bone marrowaugmented recipients toward a lower response to donor - (239) ... (302) - (225) - (220) ... (274) + (246) + (199) + (109) .... (11) + (35) ... (183) - (185) + (66) ... (36) + (36) 
NO
- (107) - (231) - (205) - (36) • Expressed as percent of donor cells detected in peripheral blood monocvtes or the recipIent.
DL = double lung;
!'lID = not done either due to short iollow-up or lack 01 adequate \'olume of sample; NF = not feasible; POD = postoperative day; SL = single lung.
as compared with third party alloantigens when tested serially during the first 6 months after transplantation.
Comment
The use of bone marrow-derived cells (splenocvtes) to achieve donor-specific transplantation tolerance in neonatal mice was first reported by Billingham and associates [II] . Subsequently, chimerism with donor-specific transplantation tolerance was achieved in adult animal models bv preconditioning the host with diJIerent regimens, which have included, among others, total body irradiation [12] , total lymphoid irradiation [13] , and the use of antilvmphocyte globulin [14] . The clinical use of donor bone marrow to prolong the survival of organ allografts was first attempted in kidney transplant recIpients. Monaco and associates 1131 first reported the use ot antilymphocyte globulin and delaved (25 davs atter organ transplantationl donor bone marrow infusion in a kidney transplant recipient. The patient had no rejection during the postoperative follow-up until she died 8 months after transplantation of fatal pentonitis, secondary to perforated sigmoid diverticulitis. There was evidence ot donor red cell chimerism; however, it did not persist after the first month, and no white cell chimerism was detected for up to 21/2 months after transplantation. Barber and associates [161 used a similar regimen in recipients of cadaveric donor kidneys who were preconditioned with antilymphocyte globulin, cvciosporine, azathioprine, and prednisone before adjuvant donor bone marrow infusion. Graft survival in the bone marrow-augmented patients was significantlv better than in contemporaneous controls, and other clin'ical evidence of benefit was also present, including a reduced need for immunosuppression and a lower incidence ot rejection in bone marrow-augmented chimeric recipients. Furthermore, donor cell chimerism was detected in 300~, to 36% of patients 3 to 12 months after transplantation [171· However, using a similar approach, Rolles and colleagues [181 were unable to show anv distinct advantage that was atforded by delayed bone ~arrow transplantation to liver allograft recipients. In 1984, Kahn and co-workers [191 reported the combined simultaneous infusion of donor bone marro\\' to 6 heart transplant recipients who were preconditioned (7 to 13 days earlier) with a total of 3,4 to 6.0 Gv ot total lvmphoid irradiation. Four patients died within '-; months of either primarv graft failure (n = 1), chronic rejection (n = 1)' or Intection In = 21. Furthermore. in the 2 patients who survived for 2 to -I years <ltter transplantation, donor-~pe(lIic hvporeactivitv Ibv \lLRl W<lS evidenced in 1. whereas it was not tested'in the other 1191. The higher incidence llt infection in patients in this ~tud\" was ,lttributed to <l combination of high dose of ~teroids and total lvmphoid irradiation.
. These clinical studies were based on the premise that "space" needs to be created by rreconditionin~ or the host with c\'toreductive or cvtoablatiye therapv, thus .l!lowing tor engrattment of donor bone marrmv with subsequent establishment and perpetuation ot chimerism. However. we ~nd others have recently demonstrated that donor chimerism is J naturallv' occurnng phenomenon after transplantation or ~olid organs, includin~ the liver Ill, kidney 121, heart [31. . .lOd lung HI· This low level of donor cell chimerism was present in all long-term ~urviving kidnev [21 and liver III recipients. Its beneticial effects were most noticeable in lung allogratt recipients. In whom donor cell chimensm was aSSOCIated with .1 lower Incidence ot bronchiolitis obliterans [-II· These observ.1tions provided the toundation tor the initiation ot the current studv, in which unmodified MHCmIsmatched donor bone marrow cdls were intused into heart or lun~ recipients at the ttme ot organ placement WIthout ,lnv rreconditioninll; ot that host or deviation trom the routine dru~s and their therapeutic doses that were required for maintenance of adequate immunosuppression.
The preliminary data from this pilot study indicate that the infusion of unmodified donor bone marrow concurrentlv with heart or lung transplantation is safe, and is associated with an increased level of donor cell chimerism. Furthermore, the early immunologic events after cardiac transplantation appear to have been altered bv the infusion of donor bone marrow. Although not stati;-tically significant, there was a trend toward a lower incidence of rejection within the first 100 days after transplantation in the bone marrow-augmented heart recipients as compared with Similarly treated historical controls. However, there was no in vitro evidence of donor-specific hypo reactivity in the serial MLR analysis performed during the first 6 months after transplantation.
Although the eventual effect of the augmented chimerism remains speculative, it is conceivable that its presence would enhance the acceptance and survival of the graft and reduce the incidence of chronic rejection. DISCUSSION DR BRUCE A. REITZ (Stanford. CAl: Doctor Pham should be congratulated for his presentation and Drs Griffith and Starzl for this very difficult clinical trial. They have demonstrated in their patients in these early results an increased incidence of microchimerism when compared with concurrent controls, and their hypothesis is that this chimerism will result in better long-term acceptance of the gratt and perhaps a decrease in chronic rejection. Most previous work on bone marrow infusion at the time of transplantation has attempted to create donor-specific tolerance, perhaps an unacceptable or unobtainable clinical goal at the present time. but when bone marrow has been given it has usually been accompanied with some type of induction therapy, such as total lymphoid irradiation, whole body radiation, or antithymocyte globulin. My first question for Dr Pham is whv induction therapy was not used in these patients. Even antithymocyte globulin alone would provide some induction. and antithymocyte globulin has been used as part of the lung transplant protocols at Pittsburgh in the past.
Second, Dr Pham, can you comment on how vou might achieve a decrease in chronic rejection if there has been no significant decrease in the early rejection frequency or a significant increase in donor-specific hyporeactivity? I think vour data show trends in this regard but the manuscript clearlv shows that at this point there is no statistical dUference.
Third, would you share with us some of the studies of FK 506 and donor bone marrow infusion and how this combination compares with cyclosporine in terms of chimerism induction?
Finally. the lack of gratt-versus-host disease is very encouraging in this study. but I would give a word of caution in that in experiments that we have done with bone marrow intuslOn. the exact combination of accompanvmg immunosuppressIon IS extremelv important and minor changes can result in either hvpersensitivitv or. on the other hand, the induction 01 tolerance. So it is verY important to have a very specific protocol and to foUow it very close Iv. Doctor Pham. please comment on graft-versus-host disease In recipients of liver transplant and how those protocols might differ from vour heart protocoi.
Again. congratulations on what is a very difficult clinical stud\".
We look forward next vear or perhaps the vear after to getting the long-term iollow-up to see if your hypothesis has been validated. had used antithymocyte globulin induction in their combined kidney-bone marrow trial and had observed an increase in the level of chimerism. However, their protocol was different from ours in that they had infused frozen bone marrow cells approximately 21 davs after the patient had receIved a kidnev transplant. \Ve did not use preoperative radiation because of our concern for subjecting the patients to a higher risk of graft-versus-host-disease. and because of the difficult logistics due to the time constraint.
On vour question about chronic rejection. the onlv available data on chimensm and chronic rejection are those reported by nur group. We had shown that lung recipients with microchimerism had a lower risk of obliterative bronchiolitis development. These data torm the basis lor the current mal.
We have not used cvc!osporine in recipIents ot combined hone marrow and heart or lung transplants. To date. we have not seen gratt-versus-host disease in heart. lung. or kidnev recipients who received concurrent bone marrow infuSIOn. However. mild gratt-versus-host disease developed in 2 of the 28 liverbone marrow recipients. The graft-versus-host disease resolved ~pontaneousl\' In 1. and with an increase in the prednisone dose from 7.S mgldav to 15 mg/dav in another.
